Videos

Mutation Testing at Progression of ALK-Rearranged NSCLC

August 2nd 2017

Brigatinib at Disease Progression of ALK-Rearranged NSCLC

August 2nd 2017

Therapeutic Options at Progression of ALK-Rearranged NSCLC

August 2nd 2017

Treatment of Newly Diagnosed ALK-Rearranged NSCLC

August 2nd 2017

Options for Upfront Treatment of ALK-Rearranged NSCLC

August 2nd 2017

Diagnosis of Metastatic ALK-Rearranged NSCLC

August 2nd 2017

<em>ALK</em>-Translocated Non-Small Cell Lung Cancer With Bone Metastases

August 2nd 2017

ALK-Translocated Non-Small Cell Lung Cancer With Bone Metastases

Multidisciplinary Management of GIST

July 26th 2017

Toxicity Management for GIST Third-Line Therapy

July 26th 2017

Third-Line Therapy for GIST

July 26th 2017

Sunitinib Therapy at Progression of Metastatic GIST

July 26th 2017

Imatinib Therapy for Resectable GIST

July 26th 2017

Diagnosis of Metastatic GIST

July 26th 2017

Recurrent Metastatic Gastrointestinal Stromal Tumor

July 26th 2017

Recurrent Metastatic Gastrointestinal Stromal Tumor

Primary Myelofibrosis Therapeutic Response Assessment

July 24th 2017

Treatment for Primary Myelofibrosis

July 24th 2017

Diagnosis/Risk Classification for Primary Myelofibrosis

July 24th 2017

High-Risk Primary Myelofibrosis

July 24th 2017

High-Risk Primary Myelofibrosis

Polycythemia Vera: JAK2 Inhibitor Patient Selection

July 24th 2017

Laboratory Monitoring for Polycythemia Vera

July 24th 2017

Inadequately Controlled Polycythemia Vera

July 24th 2017

Diagnosis of Intermediate-Risk Polycythemia Vera

July 24th 2017

Hydroxyurea Resistant Polycythemia Vera

July 24th 2017

Hydroxyurea Resistant Polycythemia Vera

Clinical Experience With Dabrafenib/Trametinib in NSCLC

July 21st 2017

Dabrafenib and Trametinib in BRAF-Mutated NSCLC

July 21st 2017

BRAF Molecular Testing in NSCLC

July 21st 2017

A Case of BRAF-Mutated NSCLC

July 21st 2017

Treatment of BRAF Mutated Non-Small Cell Lung Cancer

July 21st 2017

Treatment of BRAF Mutated Non-Small Cell Lung Cancer

Sequencing of Therapies in ALK+ NSCLC

July 19th 2017

Therapy Options at Progression in ALK+ NSCLC

July 19th 2017

Videos

Mutation Testing at Progression of ALK-Rearranged NSCLC

Brigatinib at Disease Progression of ALK-Rearranged NSCLC

Therapeutic Options at Progression of ALK-Rearranged NSCLC

Treatment of Newly Diagnosed ALK-Rearranged NSCLC

Options for Upfront Treatment of ALK-Rearranged NSCLC

Diagnosis of Metastatic ALK-Rearranged NSCLC

<em>ALK</em>-Translocated Non-Small Cell Lung Cancer With Bone Metastases

Multidisciplinary Management of GIST

Toxicity Management for GIST Third-Line Therapy

Third-Line Therapy for GIST

Sunitinib Therapy at Progression of Metastatic GIST

Imatinib Therapy for Resectable GIST

Diagnosis of Metastatic GIST

Recurrent Metastatic Gastrointestinal Stromal Tumor

Primary Myelofibrosis Therapeutic Response Assessment

Treatment for Primary Myelofibrosis

Diagnosis/Risk Classification for Primary Myelofibrosis

High-Risk Primary Myelofibrosis

Polycythemia Vera: JAK2 Inhibitor Patient Selection

Laboratory Monitoring for Polycythemia Vera

Inadequately Controlled Polycythemia Vera

Diagnosis of Intermediate-Risk Polycythemia Vera

Hydroxyurea Resistant Polycythemia Vera

Clinical Experience With Dabrafenib/Trametinib in NSCLC

Dabrafenib and Trametinib in BRAF-Mutated NSCLC

BRAF Molecular Testing in NSCLC

A Case of BRAF-Mutated NSCLC

Treatment of BRAF Mutated Non-Small Cell Lung Cancer

Sequencing of Therapies in ALK+ NSCLC

Therapy Options at Progression in ALK+ NSCLC

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Lurbinectedin Contributes to Maintenance of Response in ES-SCLC

LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors

Melanoma Survival Is Tied to Comorbidity Burden, Illuminating Care Opportunities

Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma

JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update